In this issue:
Adalimumab biosimilar vs. originator for advanced CD
Loss of anti-TNFα response depends on treatment duration in IBD
Pharmacokinetics of subcutaneous infliximab biosimilar in IBD
Thiopurine dose optimisation by NUDT15 genotype to reduce leucopenia
Consensus statement on TDM of biologics in IBD
Histological outcomes with vedolizumab vs. adalimumab for UC
Infliximab attenuates immunogenicity to COVID-19 vaccines
Monitoring after azathioprine withdrawal for IBD in deep remission
Real-world vedolizumab and anti-TNFα in biologic-naïve IBD
FMT for chronic pouchitis
Please login below to download this issue (PDF)